149 related articles for article (PubMed ID: 29073846)
1. The incidence of non-melanoma skin cancer and post-transplant lympho-proliferative disorders in the Scottish cardiac transplant population and the provision of specialist dermatological follow-up.
McPherson I; Kirk A
Scott Med J; 2018 Feb; 63(1):3-10. PubMed ID: 29073846
[TBL] [Abstract][Full Text] [Related]
2. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients.
Swinnen LJ; Costanzo-Nordin MR; Fisher SG; O'Sullivan EJ; Johnson MR; Heroux AL; Dizikes GJ; Pifarre R; Fisher RI
N Engl J Med; 1990 Dec; 323(25):1723-8. PubMed ID: 2100991
[TBL] [Abstract][Full Text] [Related]
3. Non-melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy.
Geusau A; Dunkler D; Messeritsch E; Sandor N; Heidler G; Rödler S; Ankersmit J; Zuckermann A; Tschachler E
Int J Dermatol; 2008 Sep; 47(9):918-25. PubMed ID: 18937654
[TBL] [Abstract][Full Text] [Related]
4. Impact of the posttransplant lymphoproliferative disorder subtype on survival.
Koff JL; Li JX; Zhang X; Switchenko JM; Flowers CR; Waller EK
Cancer; 2018 Jun; 124(11):2327-2336. PubMed ID: 29579330
[TBL] [Abstract][Full Text] [Related]
5. Rabbit antithymocyte globulin. A 10-year experience in cardiac transplantation.
Copeland JG; Icenogle TB; Williams RJ; Rosado LJ; Butman SM; Vasu MA; Sethi GK; McDonald AN; Klees E; Rhenman MJ
J Thorac Cardiovasc Surg; 1990 May; 99(5):852-60. PubMed ID: 2329823
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG
J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
[TBL] [Abstract][Full Text] [Related]
7. Superior Patient and Graft Survival in Adult Liver Transplant with Rabbit Antithymocyte Globulin Induction: Experience with 595 Patients.
Montenovo MI; Jalikis FG; Li M; Yeh M; Dick A; Hansen R; Reyes JD
Exp Clin Transplant; 2017 Aug; 15(4):425-431. PubMed ID: 27309029
[TBL] [Abstract][Full Text] [Related]
8. Skin tumours in the West of Scotland renal transplant population.
Mackintosh LJ; Geddes CC; Herd RM
Br J Dermatol; 2013 May; 168(5):1047-53. PubMed ID: 23137036
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant lymphoproliferative disorder following pediatric heart transplantation.
Mendoza F; Kunitake H; Laks H; Odim J
Pediatr Transplant; 2006 Feb; 10(1):60-6. PubMed ID: 16499589
[TBL] [Abstract][Full Text] [Related]
10. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
[TBL] [Abstract][Full Text] [Related]
11. Occurrence of lymphoproliferative disorder after heart transplantation is related to the total immunosuppressive load.
Brouwer RM; Balk AH; Weimar W
Transpl Int; 1992; 5 Suppl 1():S259-61. PubMed ID: 14621795
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants.
Lentine KL; Schnitzler MA; Xiao H; Brennan DC
Trials; 2015 Aug; 16():365. PubMed ID: 26285695
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol.
Ladowski JS; Dillon T; Schatzlein MH; Peterson AC; Deschner WP; Beatty L; Sullivan M; Scheeringa RH; Clark WR
J Cardiovasc Surg (Torino); 1993 Apr; 34(2):135-40. PubMed ID: 8320247
[TBL] [Abstract][Full Text] [Related]
14. Effects of Ideal Versus Total Body Weight Dosage of Rabbit Antithymocyte Globulin on Outcomes of Kidney Transplant Patients With High Immunologic Risk.
Vacha M; Gommer J; Rege A; Sanoff S; Sudan D; Harris M
Exp Clin Transplant; 2016 Oct; 14(5):511-517. PubMed ID: 26742693
[TBL] [Abstract][Full Text] [Related]
15. Malignancy After Heart Transplantation Under Everolimus Versus Mycophenolate Mofetil Immunosuppression.
Wang YJ; Chi NH; Chou NK; Huang SC; Wang CH; Wu IH; Yu HY; Chen YS; Tsao CI; Shun CT; Tsai JT; Wang SS
Transplant Proc; 2016 Apr; 48(3):969-73. PubMed ID: 27234781
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation.
Costanzo-Nordin MR; O'Sullivan EJ; Johnson MR; Winters GL; Pifarre R; Radvany R; Zucker MJ; Scanlon PJ; Robinson JA
J Heart Transplant; 1990; 9(3 Pt 2):306-15. PubMed ID: 2113094
[TBL] [Abstract][Full Text] [Related]
17. Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients.
Khanmoradi K; Knorr JP; Feyssa EL; Parsikia A; Jawa P; Dinh DB; Campos S; Zaki RF; Ortiz JA
Exp Clin Transplant; 2013 Jun; 11(3):222-8. PubMed ID: 23432665
[TBL] [Abstract][Full Text] [Related]
18. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
[TBL] [Abstract][Full Text] [Related]
19. Skin cancers in renal transplant recipients: a description of the renal transplant cohort in Bern.
Keller B; Braathen LR; Marti HP; Hunger RE
Swiss Med Wkly; 2010; 140():w13036. PubMed ID: 20652847
[TBL] [Abstract][Full Text] [Related]
20. Comparative trial of immunoprophylaxis with RATG versus OKT3.
Griffith BP; Kormos RL; Armitage JM; Dummer JS; Hardesty RL
J Heart Transplant; 1990; 9(3 Pt 2):301-5. PubMed ID: 2113093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
